At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 133 enrolled
Drug / intervention
GW876008 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008
In Brief
A Phase 2 clinical trial evaluating GW876008 and Placebo for Irritable Bowel Syndrome (IBS). Completed, enrolled 133 participants across 23 sites in 2 countries.
Detailed Summary
This is a double-blind, placebo-controlled, randomised crossover study to investigate the efficacy and safety of GW876008
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome (IBS)
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
First PostedJan 2007
Primary CompletionJun 2008
TodayJul 2026
First PostedJan 12, 2007
Enrollment StartOct 14, 2006
Primary CompletionJun 25, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.5 years ago
Interventions
GW876008drug
Placeboother